DOCSLIB.ORG

Drugs Affecting the Cardiovascular System (Tutorial)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Drugs Affecting the Cardiovascular System (Tutorial) Drugs affecting the Cardiovascular System (Tutorial) Therapeutic Classes • Antianginal • Antiarrhythmic • Antihypertensive • Cardioinhibitory • Cardiostimulatory • Diuretics • Pressor • Thrombolytic • Vasoconstrictor • Vasodilator Clinical Disorders • Angina • Arrythmias • Edema • Heart Failure • Hypertension • Hypotension • Myocardial Infarction Drug Mechanism Classes • Adenosine receptor agonist • Aldosterone receptor antagonists • Alpha-agonists • Alpha-blockers • Angiotensin-converting enzyme (ACE inhibitors) • Angiotensin Receptor blockers (ARBs) • Beta agonists • Beta blockers • Calcium-channel blockers • Centrally acting sympatholytics • Direct-acting vasodilators • Diuretics (loop,thiazide,potassium-sparing) • Endothelin receptor antagonists • Fibrinolytics • Ganglionic blockers • Muscarinic receptor antagonists • Cardiac glycosides • Natriuretic peptides • nitrodilators • Phosphodiesterase inhibitors • Potassium channel blockers • Potassium channel openers • Renin inhibitors • Sodium channel blockers • Sodium channel blockers (late sodium currents) • Sympathomimetics • Thrombolytics (fibrinolytics) • Vasopressin analogs • Antianginal Drugs • Therapeutic use & rationale • Redn in O2 supply/demand ratio • Improve this ratio • Increase blood flow – increases O2 delivery & supply • Decrease O2 demand – decrease myocardial O2 consumption • Prevent vasospasm & clot formation • Classes of Drugs Used to Treat Angina • Vasodialtors – dilate arteries & veins - Calcium channel blockers - Nitrodilators • Cardioinhibitory drugs – reduce heart rate & contractility - Beta blockers - Calcium channel blockers • Late soudium current blockers - Ranolazine • Anti-thrombotic drugs – prevent thrombus formation - Anticoagulants - Anti-platelet drugs • Calcium channel blockers (CCBs) MoA • Block calcium entry into cells of vascular sm, cardiac myocytes, cardiac nodal tissue • Cause vascular sm relaxation= vasodilation = decrease myocardial force generation = decrease heart rate = decreases conduction velocity in the heart Indications • Hypertension • Angina • Arrythmias • Classes of Calcium-Channel Blockers Dihydropyridines - Amlodipine - Felodipine - Isradipine - Nicardipine - Nifedipine - Nimodipine - Nitrendipine • smooth muscle selective • Mainly used to reduce systemic vascular resistance & arterial pressure • Mainly used to rx hypertension • Can lead to reflex cardiac stimulation (tachycardia & increased ionotropy) = increase myocardial O2 demand Non-dihydropyridines • Phynylalkylamine – verapamil - reduces myocardial oxygen demand - reverses coronary vasospasm and arrhythmias. • Benzothiazepine - Diltiazem - Cardiac depressant properties - Vasodilator actions - Reduces arterial pressure without the reflex cardiac stimulation caused by dihydropyridines. Side effects • Flushing • Headache • Excessive hypotension • Edema • Reflex tachycardia • Antiarrhythmic Drugs • Goal = to restore normal rhythm & conduction • Antiarrhythmic drugs are used to: • decrease or increase conduction velocity • alter the excitability of cardiac cells by changing the duration of the effective refractory period • suppress abnormal automaticity • Antiarrhythmic Drug Classes • Class I – Sodium channel blockers • Class II – Beta blockers • Class II – Potassium Channel blockers • Class IV – calcium channel blockers • Miscellaneous – adenosine, electrolyte supplements (mg & K salts), cardiac glycosides, atropine (muscarinic receptor antagonist) Condition Drug Comments Other underlying causes may need Sinus tachycardia Class II, IV treatment Class IA, IC, II, III, IV Ventricular rate control is important Atrial fibrillation/flutter digitalis goal; anticoagulation required adenosine Paroxysmal supraventricular Class IA, IC, II, III, IV tachycardia adenosine AV block atropine Acute reversal Ventricular tachycardia Class I, II, III Class II, IV PVCs are often benign and not Premature ventricular complexes Mg++ salts treated Class IB Digitalis toxicity Mg++ salts; KCl • Antihypertensive Drugs • Rationale for Pharmacologic Treatment of Hypertension - Reduce cardiac output 1) reduce blood volume - reduces central venous pressure and cardiac output 2) reduce systemic vascular resistance –dilate systemic vasculature 3) reduce cardiac output by depressing heart rate and stroke volume - • Drugs Used to Treat Hypertension Diuretics - thiazide diuretics - Loop diuretics - Potassium sparing diuretics Vasodilators • Alpha blockers • Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors) • Angiotensin Receptor Blockers (ARBs) • Calcium-channel blockers • Direct acting arterial dilators • Ganglionic blockers • Nitrodilators • Potassium-channel openers • Renin inhibitors Cardio-inhibitory Drugs • Beta blockers • Calcium channel blockers Centrally Acting sympatholytics • Mechanisms of diuretic drugs • Diuretic drugs increase urine output by the kidney = promote diuresis • altering how the kidney handles sodium • If the kidney excretes more sodium, then water excretion will also increase • Most diuretics inhibit the reabsorption of sodium at different segments of the renal tubular system Loop diuretics • inhibit the sodium-potassium-chloride co- transporter in the thick ascending limb • This transporter normally reabsorbs about 25% of the sodium load • inhibition of this pump can lead to a significant increase in the distal tubular concentration of sodium - reduced hypertonicity of the surrounding interstitium, and - less water reabsorption in the collecting duct = increased water loss = diuresis = increased sodium loss = natriuresis • Loop diuretics act on the thick ascending limb, which handles a significant fraction of sodium re-absorption • loop diuretics are very powerful diuretics. • These drugs also induce renal synthesis of prostaglandins, which contributes to their renal action including the increase in renal blood flow and redistribution of renal cortical blood flow. Thiazide diuretics • the most commonly used diuretic, inhibit the sodium-chloride transporter in the distal tubule. • this transporter normally only reabsorbs about 5% of filtered sodium • these diuretics are less efficacious than loop diuretics in producing diuresis and natriuresis. • But are sufficiently powerful to satisfy most therapeutic needs requiring a diuretic. • Their mechanism depends on renal prostaglandin production. • loop and thiazide diuretics increase increases potassium loss (potentially causing hypokalemia) because the increase in distal tubular sodium concentration stimulates the aldosterone-sensitive sodium pump to increase sodium re-absorption in exchange for potassium and hydrogen ion, which are lost to the urine. • Potassium-sparing Diuretics. • do not act directly on sodium transport • Some drugs in this class antagonize the actions of aldosterone (aldosterone receptor antagonists) • more sodium (and water) to pass into the collecting duct and be excreted in the urine. • They are called K+-sparing diuretics because they do not produce hypokalemia like the loop and thiazide diuretics • often used in conjunction with thiazide or loop diuretics to help prevent hypokalemia Carbonic anhydrase inhibitors • inhibit the transport of bicarbonate out of the proximal convoluted tubule into the interstitium • leads to less sodium re-absorption • greater sodium, bicarbonate and water loss in the urine • the weakest of the diuretics and seldom used in cardiovascular disease. • Their main use is in the treatment of glaucoma. Cardiovascular effects of diuretics • decrease blood volume and venous pressure • decreased cardiac filling (preload) • decreased ventricular stroke volume • Venodilation • Reduced systemic vascular resistance (long term use) THERAPEUTIC USES OF DIURETICS • Hypertension • Heart Failure – reduces pulmonary & systemic congestion & edema • Most patients in heart failure are prescribed Loop diuretics- are more effective in unloading sodium and water than thiazide diuretics. • In mild heart failure, a thiazide diuretic may be used. • Potassium-sparing, aldosterone-blocking diuretics (e.g., spironolactone) are being used increasingly in heart failure. Class Specific Drugs Comments Thiazide chlorothiazide thiazide-like in chlorthalidone action, not structure hydrochlorothiazide prototypical drug; hydroflumethiazide thiazide-like in indapamide action, not structure methyclothiazide thiazide-like in metolazone action, not structure polythiazide Loop bumetanide ethacrynic acid furosemide torsemide distal tubule Na+- K+-sparing amiloride channel inhibitor aldosterone receptor antagonist; fewer side eplerenone effects than spironolactone aldosterone receptor spironolactone antagonist; side effect: gynecomastia distal tubule Na+- triamterene channel inhibitor prototypical drug; not used in treating CA inhibitors acetazolamide hypertension or heart failure not used in treating dichlorphenamide hypertension or heart failure not used in treating methazolamide hypertension or heart failure • Adverse Side Effects and Contraindications • Cardioinhibitory Drugs • Cardioinhibitory drugs depress cardiac function by decreasing heart rate (chronotropy) and myocardial contractility (inotropy), which decreases cardiac output and arterial pressure • These cardiac changes reduce the work of the heart and myocardial oxygen consumption • The mechanisms of action of these drugs also lead to depressed electrical conduction(dromotropy) within the heart. • Some of these drugs may also impair relaxation (lusitropy). Therapeutic Uses of Cardioinhibitory Drugs • Hypertension • Angina • Arrhythmias • Heart failure
Load more

Recommended publications
  • Association of Hypertensive Status and Its Drug Treatment with Lipid and Haemostatic Factors in Middle-Aged Men: the PRIME Study
    Journal of Human Hypertension (2000) 14, 511–518 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh ORIGINAL ARTICLE Association of hypertensive status and its drug treatment with lipid and haemostatic factors in middle-aged men: the PRIME Study P Marques-Vidal1, M Montaye2, B Haas3, A Bingham4, A Evans5, I Juhan-Vague6, J Ferrie`res1, G Luc2, P Amouyel2, D Arveiler3, D McMaster5, JB Ruidavets1, J-M Bard2, PY Scarabin4 and P Ducimetie`re4 1INSERM U518, Faculte´ de Me´decine Purpan, Toulouse, France; 2MONICA-Lille, Institut Pasteur de Lille, Lille, France; 3MONICA-Strasbourg, Laboratoire d’Epide´miologie et de Sante´ Publique, Strasbourg, France; 4INSERM U258, Hoˆ pital Broussais, Paris, France; 5Belfast-MONICA, Department of Epidemiology, The Queen’s University of Belfast, UK; 6Laboratory of Haematology, La Timone Hospital, Marseille, France Aims: To assess the association of hypertensive status this effect remained after multivariate adjustment. Cal- and antihypertensive drug treatment with lipid and hae- cium channel blockers decreased total cholesterol and mostatic levels in middle-aged men. apoproteins A-I and B; those differences remained sig- Methods and results: Hypertensive status, antihyperten- nificant after multivariate adjustment. ACE inhibitors sive drug treatment, total and high-density lipoprotein decreased total cholesterol, triglycerides, apoprotein B (HDL) cholesterol, triglyceride, apoproteins A-I and B, and LpE:B; and this effect remained after multivariate lipoparticles LpA-I,
    [Show full text]
  • The Role of Intercalated Cell Nedd4–2 in BP Regulation, Ion Transport, and Transporter Expression
    BASIC RESEARCH www.jasn.org The Role of Intercalated Cell Nedd4–2 in BP Regulation, Ion Transport, and Transporter Expression Masayoshi Nanami,1 Truyen D. Pham,1 Young Hee Kim,1 Baoli Yang,2 Roy L. Sutliff,3 Olivier Staub,4,5 Janet D. Klein,1 Karen I. Lopez-Cayuqueo,6,7 Regine Chambrey,8 Annie Y. Park,1 Xiaonan Wang,1 Vladimir Pech,1 Jill W. Verlander,9 and Susan M. Wall1,10 Due to the number of contributing authors, the affiliations are listed at the end of this article. ABSTRACT Background Nedd4–2 is an E3 ubiquitin-protein ligase that associates with transport proteins, causing their ubiquitylation, and then internalization and degradation. Previous research has suggested a corre- lation between Nedd4–2 and BP. In this study, we explored the effect of intercalated cell (IC) Nedd4–2 gene ablation on IC transporter abundance and function and on BP. Methods We generated IC Nedd4–2 knockout mice using Cre-lox technology and produced global pen- 2/2 drin/Nedd4–2 null mice by breeding global Nedd4–2 null (Nedd4–2 ) mice with global pendrin null 2/2 (Slc26a4 ) mice. Mice ate a diet with 1%–4% NaCl; BP was measured by tail cuff and radiotelemetry. We 2 measured transepithelial transport of Cl and total CO2 and transepithelial voltage in cortical collecting ducts perfused in vitro. Transporter abundance was detected with immunoblots, immunohistochemistry, and immunogold cytochemistry. 2 2 Results IC Nedd4–2 gene ablation markedly increased electroneutral Cl /HCO3 exchange in the cortical col- lecting duct, although benzamil-, thiazide-, and bafilomycin-sensitive ion flux changed very little.
    [Show full text]
  • Comparing the Efficacy of Angiotensin Converting Enzyme In- Hibitors with Calcium Channel Blockers on the Treatment of Di- Abetic Nephropathy: a Meta-Analysis
    Iran J Public Health, Vol. 48, No.2, Feb 2019, pp.189-197 Review Article Comparing the Efficacy of Angiotensin Converting Enzyme In- hibitors with Calcium Channel Blockers on the Treatment of Di- abetic Nephropathy: A Meta-Analysis *Zhaowei ZHANG 1, Chunlin CHEN 2, Shiwen LV 1, Yalan ZHU 1, Tianzi FANG 1 1. Department of Pharmacy, Jin Hua Municipal Central Hospital, Jin Hua 32100, China 2. College of Chemistry and Bio-Engineering, Yi Chun University, Yi Chun 336000, China *Corresponding Author: Email: [email protected] (Received 21 Mar 2018; accepted 11 Jun 2018) Abstract Background: The angiotensin-converting enzyme inhibitors (ACEIs) could improve the symptoms of diabetic nephropathy. Whether the calcium channel blockers (CCBs) could be as effective as ACEIs on treating diabetic nephropathy is controversial. Here, we aimed to compare the efficacy of ACEIs with CCBs on the treatment of diabetic nephropathy by performing a meta-analysis of randomized controlled trials (RCTs). Methods: The Pubmed, Medline, Embase and The Cochrane Database were searched up to July 2017 for eli- gible randomized clinical trials studies. Effect sizes were summarized as mean difference (MD) or standardized mean difference (SMD) with 95% confidence intervals (P-value<0.05). Results: Seven RCTs involving 430 participants comparing ACEIs with CCBs were included. No benefit was seen in comparative group of ACEIs on systolic blood pressure（SBP） (MD=1.05 mmHg; 95% CI: -0.97 to 3.08, P=0.31), diastolic blood pressure (DBP) (MD= -0.34 mmHg; 95% CI: -1.2 to 0.51, P=0.43), urinary al- bumin excretion rates (UAER) (MD=1.91μg/min; 95% CI: -10.3 to 14.12, P=0.76), 24-h urine protein (24-UP) (SMD=-0.26; 95%CI: -0.55 to 0.03, P=0.08), glomerular filtration rate (GFR) (SMD=0.01; 95% CI: -0.38 to 0.41, P=0.95).
    [Show full text]
  • Actual Place of Diuretics in Hypertension Treatment
    Mini Review J Cardiol & Cardiovasc Ther Volume 3 Issue 4 - March 2017 Copyright © All rights are reserved by Farouk Abcha DOI: 10.19080/JOCCT.2017.03.555616 Actual Place of Diuretics in Hypertension Treatment Farouk Abcha, Marouane Boukhris*, Zied Ibn Elhadj, Lobna Laroussi, Faouzi Addad, Afef Ben Halima and Salem Kachboura Cardiology Department of Abderrahmen Mami Hospital, University of Tunis El Manar, Tunisia Submission: February 03, 2017; Published: March 07, 2017 *Corresponding author: Marouane Boukhris, Cardiology Department of Abderrahmen Mami Hospital, Ariana, Faculty of Medicine of Tunis, University of Tunis El Manar, Tunisia, Tel: ; Email: Abstract Diuretics represent a large and heterogeneous class of drugs, differing from each other by structure, site and mechanism of action. Diuretics are widely used, and have several indications in different cardiovascular disorders, particularly in hypertension and heart failure. Despite the large number of available anti-hypertensive drugs, diuretics remained a cornerstone of hypertension treatment. In the current editorial, we assessed the actual place of different diuretics in the hypertension guidelines focusing on the concept of tailored approach in prescribing them for hypertensive patients. Keywords: Diuretics; Hypertension; Hydrochlorothiazide; Indapamide; Guidelines Introduction Diuretics represent a large and heterogeneous class of drugs, differing from each other by structure, site and mechanism of action. Diuretics are widely used, and have several indications in different cardiovascular disorders, particularly in hypertension and heart failure. Despite the large number of available anti-hypertensive drugs, diuretics remained a cornerstone of hypertension treatment [1]. Indeed, they are the second most commonly prescribed class of antihypertensive medication. For instance, 12% of US adults were prescribed a diuretic, and the relative increase in prescriptions from 1999 through 2012 was 1.4 [2].
    [Show full text]
  • The Role of Intercalated Cell Nedd4–2 in BP Regulation, Ion Transport, and Transporter Expression
    BASIC RESEARCH www.jasn.org The Role of Intercalated Cell Nedd4–2 in BP Regulation, Ion Transport, and Transporter Expression Masayoshi Nanami,1 Truyen D. Pham,1 Young Hee Kim,1 Baoli Yang,2 Roy L. Sutliff,3 Olivier Staub,4,5 Janet D. Klein,1 Karen I. Lopez-Cayuqueo,6,7 Regine Chambrey,8 Annie Y. Park,1 Xiaonan Wang,1 Vladimir Pech,1 Jill W. Verlander,9 and Susan M. Wall1,10 Due to the number of contributing authors, the affiliations are listed at the end of this article. ABSTRACT Background Nedd4–2 is an E3 ubiquitin-protein ligase that associates with transport proteins, causing their ubiquitylation, and then internalization and degradation. Previous research has suggested a corre- lation between Nedd4–2 and BP. In this study, we explored the effect of intercalated cell (IC) Nedd4–2 gene ablation on IC transporter abundance and function and on BP. Methods We generated IC Nedd4–2 knockout mice using Cre-lox technology and produced global pen- 2/2 drin/Nedd4–2 null mice by breeding global Nedd4–2 null (Nedd4–2 ) mice with global pendrin null 2/2 (Slc26a4 ) mice. Mice ate a diet with 1%–4% NaCl; BP was measured by tail cuff and radiotelemetry. We 2 measured transepithelial transport of Cl and total CO2 and transepithelial voltage in cortical collecting ducts perfused in vitro. Transporter abundance was detected with immunoblots, immunohistochemistry, and immunogold cytochemistry. 2 2 Results IC Nedd4–2 gene ablation markedly increased electroneutral Cl /HCO3 exchange in the cortical col- lecting duct, although benzamil-, thiazide-, and bafilomycin-sensitive ion flux changed very little.
    [Show full text]
  • Initial Medication Selection for Treatment of Hypertension in an Open-Panel HMO
    J Am Board Fam Pract: first published as 10.3122/jabfm.8.1.1 on 1 January 1995. Downloaded from Initial Medication Selection For Treatment Of Hypertension In An Open-Panel HMO Micky jerome, PharmD, MBA, George C. Xakellis, MD, Greg Angstman, MD, and Wayne Patchin, MBA Background: During the past 25 years recommendations for treating hypertension have evolved from a stepped-care approach to monotherapy or sequential monotherapy as experience has been gained and new antihypertensive agents have been introduced. In an effort to develop a disease management strategy for hypertension, we investigated the prescribing patterns of initial medication therapy for newly treated hypertensive patients. Methods: We examined paid claims data of an open-panel HMO located in the midwest. Charts from 377 patients with newly treated hypertension from a group of 12,242 hypertenSive patients in a health insurance population of 85,066 persons were studied. The type of medication regimen received by patients newly treated for hypertension during an 18-month period was categorized into monotherapy, sequential monotherapy, stepped care, and initial treatment with multiple agents. With monotherapy, the class of medication was also reported. Associations between use of angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers, or (3-blockers and presence of comorbid conditions were reported. Results: Fifty-five percent of patients received monotherapy, 22 percent received stepped care, and 18 percent received sequential monotherapy. Of those 208 patients receiving monotherapy, 30 percent were prescribed a calcium channel blocker, 22 percent an ACE inhibitor, and 14 percent a f3-blocker. No customization of treatment for comorbid conditions was noted.
    [Show full text]
  • Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: an Overview of Systematic Reviews
    Supplementary Online Content Karmali KN, Lloyd-Jones DM, Berendsen MA, et al. Drugs for primary prevention of atherosclerotic cardiovascular disease: an overview of systematic reviews. JAMA Cardiol. Published online April 27, 2016. doi:10.1001/jamacardio.2016.0218. eAppendix 1. Search Documentation Details eAppendix 2. Background, Methods, and Results of Systematic Review of Combination Drug Therapy to Evaluate for Potential Interaction of Effects eAppendix 3. PRISMA Flow Charts for Each Drug Class and Detailed Systematic Review Characteristics and Summary of Included Systematic Reviews and Meta-analyses eAppendix 4. List of Excluded Studies and Reasons for Exclusion This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. 1 Downloaded From: https://jamanetwork.com/ on 09/28/2021 eAppendix 1. Search Documentation Details. Database Organizing body Purpose Pros Cons Cochrane Cochrane Library in Database of all available -Curated by the Cochrane -Content is limited to Database of the United Kingdom systematic reviews and Collaboration reviews completed Systematic (UK) protocols published by by the Cochrane Reviews the Cochrane -Only systematic reviews Collaboration Collaboration and systematic review protocols Database of National Health Collection of structured -Curated by Centre for -Only provides Abstracts of Services (NHS) abstracts and Reviews and Dissemination structured abstracts Reviews of Centre for Reviews bibliographic
    [Show full text]
  • RESEARCH UPDATES (Cont.)
    RESEARCH UPDATES (cont.) RESEARCH UPDATES Resident Editors: David Bunch, Pharm.D., Ally Kingsbury, Pharm.D., Monika Tawfik, Pharm.D. Faculty Editors: Sarah Schweiss, Pharm.D., BCACP RESEARCH UPDATES Volume 18, Issue 1 – First The HUNT Study: Proton Pump Inhibitors and Fracture Risk1 Quarter 2020 Kaylin Maddy, PharmD Park Nicollet Health Services Research Updates The HUNT Study: Proton Pump Background: Proton pump inhibitors (PPIs) are broadly prescribed for gastrointestinal conditions. These medications have been correlated with an increased risk of fractures Inhibitors and Fracture Risk in multiple previous studies, however a definite causative link is not well understood. A Comparison of Two LDL The FDA requires PPI packaging information to include a warning about increased hip, Cholesterol Targets after Ischemic wrist, or spine fracture risk with long term and high dose PPI use. Many mechanisms for this risk have been proposed including reduced calcium and magnesium absorption, Stroke though these have not been adequately demonstrated in humans. Therapeutic Thoughts Purpose: The Nord-Trøndelag Health Study (HUNT) study aimed to examine a possible Migraine Pharmacotherapy and association between the use of PPIs and risk of fracture in a large group of Norwegian individuals. Novel Agents Study Design: A total of 15,017 women and 13,241 men aged 50 to 85, with a mean age Antihypertensive Treatment of 65 years old were analyzed. Data was retrospectively reviewed from a large Update Norwegian Health Study (HUNT3), the Norwegian Fracture Registry, and the Norwegian Prescription Database. The fracture registry collects information on hip and Who Should Receive PCV13? forearm fractures. History of exposure to PPIs, anti-osteoporotic drugs (AODs), and oral glucocorticoids (GCs) were pulled from the prescription database.
    [Show full text]
  • Pharmacy Précis
    Samford University Global Drug Information Service PHARMACY RÉCIS P Précis: a concise summary of essential points, statements or facts Volume 30 (Issue 1) January 2012 NEW MOLECULAR ENTITIES OF 2011 New molecular entities, biologic agents, and drug formulations/combinations approved during 2011 (including indication, approval date, and comments) are presented in this issue of Pharmacy Précis. An explanation of the FDA classification of the new drugs also is included. If you need any additional information regarding these agents, please call the Samford University Global Drug Information Service at (205) 726-2659. FDA classifications for newly approved drugs are based on chemical classification and are outlined below. FDA CLASSIFICATIONS CHEMICAL CLASSIFICATION THERAPEUTIC CLASSIFICATION 1. New molecular entity - drug S = Standard review - assigned not marketed in U.S. by any to drugs that appear to have manufacturer therapeutic qualities similar to 2. New salt - active moiety is drugs already approved marketed in the U.S., but this P = Priority review - assigned particular salt, ester, or to drugs that appear to have derivative is not therapeutic gain over drugs 3. New formulation - drug currently available marketed in the U.S., but this O = Orphan designation - particular formulation is not Pursuant to Section 526 of the 4. New combination - two or Orphan Drug Act (Public Law more ingredients in 97-414 as amended). combination not marketed in 1. Providing effective therapy the U.S. or diagnosis for a disease 5. New manufacturer - already not adequately treated or marketed by another firm; diagnosed by any marketed duplicated salt, formulation or drug combination 2. Providing improved 6.
    [Show full text]
  • Self-Measured Compared to Office
    Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Supplemental Tables and Figures Part 1: Self-Measured Compared to Office-Based Measurement of Blood Pressure in the Management of Adults With Hypertension Table 1.1 Electronic search terms used for the current meta-analysis (Part 1 – Self-Measured Compared to Office-Based Measurement of Blood Pressure in the Management of Adults With Hypertension). PubMed Search (Blood Pressure Monitoring, Ambulatory [mesh] OR self care [mesh] OR telemedicine [mesh] OR patient participation [tiab] OR ambulatory [tiab] OR kiosk [tiab] OR kiosks [tiab] OR self-monitor* [tiab] OR self-measure* [tiab] OR self-care* [tiab] OR self-report* [tiab] OR telemonitor* [tiab] OR tele-monitor* [tiab] OR home monitor* [tiab] OR telehealth [tiab] OR tele-health [tiab] OR telemonitor* [tiab] OR tele-monitor* [tiab] OR telemedicine [tiab] OR patient-directed [tiab] OR Blood pressure monitoring “patient directed” [tiab] OR HMBP [tiab] OR SMBP [tiab] OR home [tiab] OR white coat [tiab] OR concept + Self Care concept ((patient participation [ot] OR ambulatory [ot] OR kiosk [ot] OR kiosks [ot] OR self-monitor* [ot] OR self-measure* [ot] OR self-care* [ot] OR self-report* [ot] OR telemonitor* [ot] OR tele-monitor* [ot] OR home monitor* [ot] OR telehealth [ot] OR tele-health [ot] OR telemonitor* [ot] OR tele- monitor* [ot] OR telemedicine [ot] OR patient-directed [tiab] OR “patient directed” [tiab]
    [Show full text]
  • Australian Public Assessment Report for Aliskiren, Amlodipine and Hydrochlorothiazide Proprietary Product Name: Rasilamlo HCT
    Australian Public Assessment Report for Aliskiren, Amlodipine and Hydrochlorothiazide Proprietary Product Name: Rasilamlo HCT Sponsor: Novartis Pharmaceuticals Australia Pty Ltd June 2012 Therapeutic Goods Administration About the Therapeutic Goods Administration (TGA) · The Therapeutic Goods Administration (TGA) is a division of the Australian Government Department of Health and Ageing, and is responsible for regulating medicines and medical devices. · TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when necessary. · The work of the TGA is based on applying scientific and clinical expertise to decision- making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. · The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. · To report a problem with a medicine or medical device, please see the information on the TGA website. About AusPARs · An Australian Public Assessment Record (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission. · AusPARs are prepared and published by the TGA. · An AusPAR is prepared for submissions that relate to new chemical entities, generic medicines, major variations, and extensions of indications. · An AusPAR is a static document, in that it will provide information that relates to a submission at a particular point in time. · A new AusPAR will be developed to reflect changes to indications and/or major variations to a prescription medicine subject to evaluation by the TGA.
    [Show full text]
  • Systematic Evidence Review from the Blood Pressure Expert Panel, 2013
    Managing Blood Pressure in Adults Systematic Evidence Review From the Blood Pressure Expert Panel, 2013 Contents Foreword ............................................................................................................................................ vi Blood Pressure Expert Panel ..............................................................................................................vii Section 1: Background and Description of the NHLBI Cardiovascular Risk Reduction Project ............ 1 A. Background .............................................................................................................................. 1 Section 2: Process and Methods Overview ......................................................................................... 3 A. Evidence-Based Approach ....................................................................................................... 3 i. Overview of the Evidence-Based Methodology ................................................................. 3 ii. System for Grading the Body of Evidence ......................................................................... 4 iii. Peer-Review Process ....................................................................................................... 5 B. Critical Question–Based Approach ........................................................................................... 5 i. How the Questions Were Selected ................................................................................... 5 ii. Rationale for the Questions
    [Show full text]